Cancer immunotherapy is usually achieved by targeting ICGs such as antibody inhibition of PD-1 and CTLA-4, but its clinical efficacy largely depends on the individual tumor immune microenvironment and immune-related regulatory networks [33], which underscores the importance of understanding how immune checkpoint genes orchestrate TME patterns and affect patients' prognostic outcomes. The gene discussed is CTLA4; the disease is cancer.